Literature DB >> 21355612

Structural, electronic, and acid/base properties of [Ru(bpy)2(bpy(OH)2)]2+ (bpy = 2,2'-bipyridine, bpy(OH)2 = 4,4'-dihydroxy-2,2'-bipyridine).

Samantha Klein1, William G Dougherty, W Scott Kassel, Timothy J Dudley, Jared J Paul.   

Abstract

We have synthesized the complex [Ru(bpy)(2)(bpy(OH)(2))](2+) (bpy =2,2'-bipyridine, bpy(OH)(2) = 4,4'-dihydroxy-2,2'-bipyridine). Experimental results coupled with computational studies were utilized to investigate the structural and electronic properties of the complex, with particular attention paid toward the effects of deprotonation on these properties. The most distinguishing feature observed in the X-ray structural data is a shortening of the CO bond lengths in the modified ligand upon deprotonation. Similar results are also observed in the computational studies as the CO bond becomes double bond in character after deprotonating the complex. Electrochemically, the hydroxy-modified bipyridyl ligand plays a significant role in the redox properties of the complex. When protonated, the bpy(OH)(2) ligand undergoes irreversible reduction processes; however, when deprotonated, reduction of the substituted ligand is no longer observed, and several new irreversible oxidation processes associated with the modified ligand arise. pH studies indicate [Ru(bpy)(2)(bpy(OH)(2))](2+) has two distinct deprotonations at pK(a1) = 2.7 and pK(a2) = 5.8. The protonated [Ru(bpy)(2)(bpy(OH)(2))](2+) complex has a characteristic UV/Visible absorption spectrum similar to the well-studied complex [Ru(bpy)(3)](2+) with bands arising from Metal-to-Ligand Charge Transfer (MLCT) transitions. When the complex is deprotonated, the absorption spectrum is altered significantly and becomes heavily solvent dependent. Computational methods indicate that the deprotonated bpy(O(-))(2) ligand mixes heavily with the metal d orbitals leading to a new absorption manifold. The transitions in the complex have been assigned as mixed Metal-Ligand to Ligand Charge Transfer (MLLCT).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21355612     DOI: 10.1021/ic1017054

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  1 in total

1.  Ruthenium dihydroxybipyridine complexes are tumor activated prodrugs due to low pH and blue light induced ligand release.

Authors:  Kyle T Hufziger; Fathima Shazna Thowfeik; David J Charboneau; Ismael Nieto; William G Dougherty; W Scott Kassel; Timothy J Dudley; Edward J Merino; Elizabeth T Papish; Jared J Paul
Journal:  J Inorg Biochem       Date:  2013-10-14       Impact factor: 4.155

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.